If I could add to that, many of the companies we work with will submit to the FDA, and then because of the way that Health Canada requires submissions, they'll submit those later. Even if we co-create a technology with them, we're the last ones to be able to use it on humans, even though we co-created that. They go to the CE first, the FDA, and then finally to Health Canada.
It would be great if we could move this innovation evaluation curve forward by having our regulations support the adoption and keep the bar high but increase the response of regulatory submissions. Then people would bring us technologies early on and we could begin this evaluation cycle. It would make our innovators who do technology development logical partnerships because we're in this environment.
I know right now, for example, we're waiting on technology that was supposed to be back from Health Canada in 70 days. The backlog is months more than that. Our industry partners globally are saying they'd love to do something sooner but they know there are impediments.
There is room to improve.